ERBB2 and gastric cancer: In a randomized phase II trial of 1st-line chemotherapy of FOLFOX with or without pazopanib (NCT01503372) enrolling 87 patients with advanced GC not expressing HER2, median PFS was 5.1 months and 3.9 months (HR 0.93 [95% CI 0.56–1.54]); median OS was 10.1 months and 7.0 months (HR 0.80 [95% CI 0.44–1.48]), respectively.